Price T Rowe Associates Inc Tcr2 Therapeutics Inc. Transaction History

Price T Rowe Associates Inc

  • $869 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.83 - $1.44 $12,201 - $21,168
14,700 Added 42.98%
48,900 $49,000
Q2 2022

Aug 15, 2022
SELL
$2.11 - $2.94 $5,445 - $7,588
-2,581 Reduced 7.02%
34,200 $99,000
Q1 2022

May 16, 2022
BUY
$2.4 - $4.71 $1,200 - $2,355
500 Added 1.38%
36,781 $102,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $166,166 - $302,583
36,281 New
36,281 $169,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email